

**AMOS OLUSEGUN ABIOYE, BPharm., Ph.D., MRPharmS, FRSC, FHEA**

**Belmont University College of Pharmacy**

**1900 Belmont Boulevard, Nashville, TN 37212**

**[amos.abioye@belmont.edu](mailto:amos.abioye@belmont.edu)**

---

---

**A. EDUCATION AND PROFESSIONAL TRAINING**

**I. Doctor of Philosophy (Ph.D.)** in *Pharmaceutics and Pharmaceutical Technology*, 2000 at the College of Medicine of the University of Lagos, Nigeria.

**II. Master of Science** in *Pharmaceutics and Pharmaceutical Technology*, 1994 at the College of Medicine of the University of Lagos, Nigeria.

**III. Bachelor of Pharmacy (BPharm.)**, 1991 at the Obafemi Awolowo University, Nigeria

**IV. Postgraduate Certificate in Higher Education (PGCert.)**, 2009 at De Montfort University, UK.

**V. Postgraduate Diploma for Overseas Pharmacists (OSPAP)**, 2010 at Aston University, UK.

**B. PROFESSIONAL LICENSURE – REGISTERED PHARMACIST**

Pharmacists' Council of Nigeria 1991

General Pharmaceutical Council (GPhC) United Kingdom 2012

**C. TEACHING EXPERIENCE**

August, 2022 – present: **Associate Professor**  
**Belmont University College of Pharmacy, Nashville, TN 37212**

*PHM 6100 Pharmaceutics I and Lab 4 Credits Fall 2022*

**Role:** Instructor (Lab)

*PHM 6140 Pharmaceutics II and Lab 4 Credits Spring 2023*

**Role:** Course Coordinator & Instructor

*PHM 6992 Advanced Extemp. Compounding 2 Credits Fall 2023*

**Role:** Course Coordinator & Instructor

July, 2018 – July, 2022: **Associate Professor**  
**Lloyd L. Gregory School of Pharmacy,**  
**Palm Beach Atlantic University, West Palm Beach, Florida**

*PRX 1114 Pharmaceutics 4 Credits Fall 2018 – 2022*

**Role:** Course Instructor

*PRX 1251 Extemp. Compounding Lab 1 Credit Spring 2018 - 2022*

**Role:** Course Coordinator & Instructor

*PRX 3592 Independent Study in Advanced Compounding 2 Credits*  
**Role:** Course Coordinator & Instructor (Spring 2018 – 2022)

*PRX 2213 Immunology, Biotech and Pharmacogenomics 3 Credits*  
**Role:** Course Instructor (Spring 2018 – 2022)

*PRX 2213 Immunology, Biotech and Pharmacogenomics 3 Credits*  
**Role:** Course Coordinator & Instructor (Spring 2022)

*PRX 2102 Healthcare Delivery System and Patient Safety 2 Credits*  
**Role:** Course Instructor (Fall 2019 – 2022)

*Inter-Professional Education (IPE) – Embedded in several courses*  
**Role:** Course Instructor

October, 2007 – June, 2018: **Senior Lecturer**  
**Leicester School of Pharmacy,**  
**De Montfort University, Leicester, United Kingdom.**

**Graduate Degree**

*PHAR 1501 Molecule to Patient 30 Credit Hours*  
**Role:** Course Coordinator & Instructor (2007 - 2012)

*PHAR 1505 Molecular Properties of Drugs 30 Credit Hours*  
**Role:** Course Instructor (2007 - 2012)

*PHAR 1604 Fundamentals of Medicine Design 30 Credit Hours*  
**Role:** Course Coordinator & Instructor (2012 - 2018)

*PHAR 1605 Foundation Skills in Pharmacy Practice 30 Credit Hours*  
**Role:** Course Instructor – Science-Practice Integration (2012 - 2018)

*PHAR 2605 Law, Ethics and Practice 30 Credit Hours*  
**Role:** Course Instructor – Science-Practice Integration (2012 - 2018)

*PHAR 3503 Pharmaceuticals: From Solution to Controlled Release 30 Credit Hours*  
**Role:** Course Coordinator & Instructor (2012 - 2014)

*PHAR 3601 Professional and Scientific Skills*  
**Role:** Course Coordinator and Instructor – Science-Practice Integration (2014 - 2018)

*PHAR 3604 Drug Discovery and Delivery 30 Credit Hours*  
**Role:** Course Instructor (2014 - 2018)

*PHAR 4503 MPharm Research Project 60 Credit Hours*  
**Role:** Course Instructor and Research Mentor (2007 - 2018)

*PHAR 5320 Microbial Fermentation and Drug Development 30 Credit Hours*  
**Role:** Course Instructor (2017 - 2018)

*PHCO 5302 Product Design: Preformulation and Formulation 30 Credit Hours*  
**Role:** Course Instructor (2017 - 2018)

### **Undergraduate Degree**

*PHCO 1301 Pharmaceutical Compounding 30 Credit Hours*

**Role:** *Course Instructor (2007 - 2018)*

*PHCO 1304 Pharmaceutical Microbiology 30 Credit Hours*

**Role:** *Course Instructor (2007 - 2018)*

*PHCO 3304 Research Project 60 Credit Hours*

**Role:** *Course Instructor and Research Mentor (2007 - 2018)*

Nov., 2000 – Sept., 2007:

**Senior Lecturer**

**Faculty of Pharmacy, University of Lagos, Nigeria.**

### **Postgraduate Degree**

*PCT 851 Tableting and Related Unit Operations 4 Credit Hours*

**Role:** *Course Instructor (2001 - 2007)*

*PCT 852 Disperse Systems 4 Credit Hours*

**Role:** *Course Coordinator & Instructor (2001 - 2007)*

*PCT 853 Formulation of Dosage Forms 4 Credit Hours*

**Role:** *Course Coordinator & Instructor (2001 - 2007)*

*PCT 854 Kinetics and Stability Studies of Dosage Forms 3 Credit Hours*

**Role:** *Course Coordinator & Instructor (2001 - 2007)*

*PCT 855 Sterilization, Disinfection and Mechanism of Action of Antimicrobial Agents 3 Credit Hours*

**Role:** *Course Instructor (2001 - 2007)*

*PCT 856 Biodegradation and Preservation of Pharmaceuticals 3 Credit Hours*

**Role:** *Course Instructor (2001 - 2007)*

*PCT 857 Antimicrobial Chemotherapy 4 Credit Hours*

**Role:** *Course Coordinator & Instructor (2001 - 2007)*

*PCT 858 Research Project 4 Credit Hours*

**Role:** *Course Instructor and Research Mentor (2001 - 2007)*

*PCT 859 Encapsulation 3 Credit Hours*

**Role:** *Course Coordinator & Instructor (2001 - 2007)*

*PCT 863 Seminar 2 Credit Hours*

**Role:** *Course Instructor (2001 - 2007)*

## **Undergraduate Degree**

*PCT 201 General Pharmaceutics 3 Credit Hours*

**Role:** Course Instructor (2000 - 2007)

*PCT 202 Physical Pharmaceutics I 4 Credit Hours*

**Role:** Course Instructor (2000 - 2007)

*PCT 203 Dispensing Practice I 4 Credit Hours*

**Role:** Course Coordinator & Instructor (2000 - 2007)

*PCT 204 Pharmaceutical Microbiology 4 Credit Hours*

**Role:** Course Instructor (2000 - 2007)

*PCT 301 Physical Pharmaceutics II 4 Credit Hours*

**Role:** Course Instructor (2000 - 2007)

*PCT 302 Pharmaceutical Technology I 4 Credit Hours*

**Role:** Course Instructor (2000 - 2007)

*PCT 303 Pharmaceutical Technology II 4 Credit Hours*

**Role:** Course Instructor (2000 - 2007)

*PCT 304 Dispensing Practice II 4 Credit Hours*

**Role:** Course Coordinator & Instructor (2000 - 2007)

*PCT 305 Disinfection and Sterilization 3 Credit Hours*

**Role:** Course Coordinator & Instructor (2000 - 2007)

*PCT 307 Forensic Pharmacy, History and Ethics 4 Credit Hours*

**Role:** Course Coordinator & Instructor (2000 - 2005)

*PCT 401 Formulation and Stability of Dosage Form 3 Credit Hours*

**Role:** Course Instructor (2000 - 2007)

*PCT 402 Pharmaceutical Technology Practical 2 Credit Hours*

**Role:** Course Coordinator & Instructor (2000 - 2007)

*PCT 403 Infection and Immunology 3 Credit Hours*

**Role:** Course Coordinator & Instructor (2000 - 2007)

*PCT 404 Fermentation, Biodegradation and Preservation of  
Pharmaceuticals 4 Credit Hours*

**Role:** Course Instructor (2000 - 2007)

*PCT 501 Industrial Pharmacy I 2 Credit Hours*

**Role:** Course Coordinator & Instructor (2000 - 2007)

*PCT 502 Industrial Pharmacy II 2 Credit Hours*

**Role:** Course Instructor (2000 - 2007)

*PCT 503 Formulation of Dosage Form 4 Credit Hours*

**Role:** Course Instructor (2000 - 2007)

*PCT 504 Product Development and Good Manufacturing Practice  
4 Credit Hours*

**Role:** Course Coordinator & Instructor (2000 - 2007)

March, 1997 – November, 2000): **Lecturer II**  
**Faculty of Pharmacy, (Shagamu Campus),  
Olabisi Onabanjo University, Ago Iwoye, Nigeria.**

***Undergraduate Degree***

*PCT 202 Physical Pharmaceutics I 4 Credit Hours*

**Role:** *Course Instructor (1997 - 2000)*

*PCT 203 Dispensing Practice I 2 Credit Hours*

**Role:** *Course Instructor (1997 - 2000)*

*PCT 301 Physical Pharmaceutics II 4 Credit Hours*

**Role:** *Course Instructor (1997 - 2000)*

*PCT 302 Pharmaceutical Technology I 4 Credit Hours*

**Role:** *Course Instructor (1997 - 2000)*

*PCT 303 Pharmaceutical Technology II 4 Credit Hours*

**Role:** *Course Instructor (1997 - 2000)*

*PCL 301 Introduction to Disease States 4 Credit Hours*

**Role:** *Course Instructor (1997 - 2000)*

**D. PROFESSIONAL WORK EXPERIENCE**

**Feb., 1994 – March 1997** **AI-Sativa Pharmaceuticals Limited Lagos, Nigeria.**

***Regulatory Affairs Manager / Quality Compliance Pharmacist***

**Responsibility:** Registration of imported drug products with NAFDAC, Nigeria; chemical analysis and clinical evaluation of imported drug products; statistical product sampling for quality control tests, quality auditing, implementation of quality assurance standard specifications, regulatory compliance assessment and validation; preparation of dossiers and documentation of standard procedures and clean report of findings; distribution of registered pharmaceutical products to the clinics of institutions like Central Bank of Nigeria and Nigerian National Petroleum Corporation.

**Dec., 1991 – Dec., 1992**

**SmithKline Beecham Nig. Plc, Lagos Nigeria.**

***Internee Pharmacist***

**Responsibility:** Quality Assurance (chemical and microbiological analysis); Quality monitoring of batch-to-batch production and manufacturing of pharmaceutical and healthcare products; All raw materials and purified water were tested before they were used for manufacturing; In-process samples and finished products were analyzed using chemical analysis and microbiological assays. All batches must pass QC tests at every stage of manufacturing process before I released them to the stores for distribution. I also conducted in-house research and development on company's products and competitors' brands.

**May, 1981 – Nov., 1986**

**Cadbury Nigeria Plc, Lagos, Nigeria**

***Quality Control Inspector / Analyst***

**Responsibility:** Batch-to-batch Quality Control monitoring of beverages and confectioneries' production / manufacturing processes, validation of manufacturing procedures, certification of raw materials before use, designing procedures for separation of products with quality defects, certification of equipment status before the next batch, process control of intermediate and finished beverage and confectionary products to meet standard quality specifications, compliance with Good Manufacturing Practice, line Inspection, approval of batches that meet quality specifications to be released for storage and distribution, inhouse research and development using locally sourced raw materials etc. Batches that "pass" by meeting the quality standard specifications are released while those that do not meet the specifications are "rejected"

## **E. LEADERSHIP, SERVICE AND ADMINISTRATIVE EXPERIENCE**

- Sub-Dean Faculty of Pharmacy, University of Lagos **2004 – 2007**
- Chair, Strategic Planning Committee Faculty of Pharmacy, University of Lagos **2005/2006**
- Chair, Postgraduate Committee, Department of Pharm. & Pharm. Tech. **2001 – 2007**
- Member, Academic Program Committee, School of Postgraduate Studies, University of Lagos **2005/06 , 2006/07**
- Member, Board of Postgraduate Studies, University of Lagos **2002 – 2007**
- Member, Examination Collation Committee, Faculty of Pharmacy, UNILAG **2000 – 2007**
- Coordinator, Student Industrial Work Experience Scheme, Faculty of Pharmacy, University of Lagos **2002 – 2007**
- Member, Graduate Assistant Recruitment Committee **2003 – 2004**
- Coordinator, Mandatory Continuing Professional Development for Pharmacists, University of Lagos Center **2003 – 2005**
- Member, Research Experimentation Committee, Faculty of Pharmacy, University of Lagos **2001 – 2007**
- Deputy MPharm Program Leader, Leicester School of Pharmacy, De Montfort University, UK – **2016 – 2018.**
- Member, Academic Quality Committee (DAQ) De Montfort University, UK – **2016**
- Member, MPharm. Program Management Board, Leicester School of Pharmacy, De Montfort University, Leicester, UK – **2008 to 2018**
- Member, MPharm. Program Assessment Board, Leicester School of Pharmacy, De Montfort University, Leicester, UK – **2008 to 2018**
- Module Leader, Molecule to Patient – PHAR 1501 – **2007 – 2012**
- Lead, Extemporaneous Dispensing Team – **2007 – 2012**
- De Montfort University Representative, Industrial Pharmacists Group of the Royal Pharmaceutical Society of Great Britain – **2008 – 2010**
- Module Leader, Formulation and Bioavailability: From Solution to Controlled Release – PHAR 3503 – **2012 – 2014**
- Module Leader, Professional and Scientific Skills 3 – PHAR 3601 – **2014 to 2018**
- Admission Tutor and West Africa Recruitment Lead for Pharmaceutical and Cosmetic Science (PCS) – **2010 to 2014**
- MPharm Year 3 Coordinator – **2013 to 2018**
- Personal tutor and professional mentor for MPharm and PCS students – **2007 to 2018**
- Chair, Curriculum and Academic Policy, Palm Beach Atlantic University – **2019 – 2020**
- Secretary, Undergraduate Program Committee, Palm Beach Atlantic University – **2019 to 2020**
- *Coordinator, Extemporaneous Compounding Practice, PBA – 2018 – to date.*

## F. PUBLICATIONS

### I. Peer Reviewed Book Chapters

1. **Amos Abioye**, 2020. *Integrated Approach to Drug Nomenclature* In: Remington: The Science and Practice of Pharmacy, 23<sup>rd</sup> Edition. Elsevier, 2020; Chapter 2.
2. Danil Hammoudi, Adekunle Sanyaolu, Nirav Nagarsheth, Jason Kimbel and **Amos Abioye**, 2019. TNF- $\alpha$  Inhibitor Treatment for Crohn's Disease: Comparative Review of Post Therapy Malignancy between Infliximab and Adalimumab In: Modern Advances in Pharmaceutical Research Vol. 2 – 2019/BP/2159.

### II. Peer Reviewed Journal Articles

3. Adekunle Sanyaolu , Chuku Okorie, Aleksandra Marinkovic, Stephanie Prakash, Martina Williams, Nafees Haider, Jasmine Mangat, Zaheeda Hosein, Vyshnavy Balendra, Abu Fahad Abbasi, Priyank Desai, Isha Jain, Stephen Utulor and **Amos Abioye**. Current advancements and future prospects of COVID-19 vaccines and therapeutics: a narrative review. *Therapeutic Advances in Vaccines and Immunotherapy*, 2022; <https://journals.sagepub.com/doi/full/10.1177/25151355221097559>.
4. **Amos Abioye**, Maitham Naqvi, Dillan Pattni and Aderonke Ayinke Adepoju-Bello, 2021. Non-intuitive Behaviour of Polymer-Ciprofloxacin Nanoconjugate Suspensions: A Tool for Flexible Oral Drug Delivery. *AAPS PharmSciTech* 22 (7): 229.  
<https://doi.org/10.1208/s12249-021-02105-8>
5. Soroh A., Owen L., Rahim N., Masania J., **Abioye A.**, Qutachi O., Goodyer L., Shen J., Laird K, 2021. Microemulsification of essential oils for the development of sustainable antimicrobial and mosquito repellent functional coatings for textiles. *Journal of Applied Microbiology* – doi:10.1111/jam.15157;  
<https://sfamjournals.onlinelibrary.wiley.com/doi/epdf/10.1111/jam.15157>
6. **Amos Abioye**, Oladapo Ayodele, Aleksandra Marinkovic, Risha Patidar, Adeola Akinwekomi, and Adekunle Sanyaolu, 2020.  $\Delta$ 9-Tetrahydrocannabinavarin (THCV): A commentary on a potential therapeutic benefit for the management of obesity and diabetes. *Journal of Cannabis Research* 2 (6) DOI: <https://doi.org/10.1186/s42238-020-0016-7>
7. **Amos Abioye**, Adekunle Sanyaolu, Paulina Dudzinska, Aderonke Ayinke Adepoju-Bello, Herbert A. B. Coker, 2020. Chitosan-induced synergy for extended antimicrobial potency and enhanced in vitro drug release of free base ciprofloxacin nanoplexes. *Pharmaceutical Nanotechnology*, 2020, 8(1): 33 – 53.
8. Okorie, C., Ajibesin, K. , Sanyaolu, A., Islam, A., Lamech, S., Mupepi, K., Mupepi, T., Oseni, A., Oyeleke, O. and **Amos Abioye**, 2019. A Review of the Therapeutic Benefits of *Moringa oleifera* in Controlling High Blood Pressure (Hypertension). *Current Traditional Medicine*, 5 (4), DOI : [10.2174/2215083805666190208163441](https://doi.org/10.2174/2215083805666190208163441)



9. Adesida, S.A., **Abioye, A.O. et al.**, 2017. Staphylococcal Bacteremia among Human Immunodeficiency virus positive patients at a screening centre in Lagos, Nigeria. *Beni-Suef University Journal of Basic and Applied Sciences* 6(2): 112 – 117.
10. Adekunle Sanyaolu, **Amos Abioye**, Bayo A., Glorius J., Ali A (2017). A review of Dalvance for the treatment of acute bacterial skin and skin structure infections (Absssis). *Global Journal of Pharmacy and Pharmaceutical Science* 2(4): 1 – 7.
11. Adeola T. Kola-Mustapha, David Armitage, **Amos Abioye** (2016). Development of aqueous *ternary* nanomatrix films: a novel 'green' strategy for the delivery of poorly soluble drugs. *International Journal of Pharmaceutics* 515: 616 – 631. DOI: 10.1016/j.ijpharm.2016.11.017
12. Adeola T. Kola-Mustapha, **Amos Abioye** (2016). Formulation and characterization of gellan-DEAE Dextran polyelectrolyte complex hydrogels. *West African Journal of Pharmacy* 27(1): 104 – 117.
13. **Amos Abioye**; George Tangyie Chi; Elena Simone; Zoltan Nagy (2016). Real-time monitoring of the influence of *in situ* granulation on aqueous crystallization of ibuprofen in ibuprofen-cationic dextran cristanules using crystallization process informatics system (CryPRINS). *International Journal of Pharmaceutics* 509: 264 – 278.
14. **Amos Abioye**; George Tangyie Chi; Adeola T. Kola-Mustapha; Ketan Ruparelia; Ken Beresford; Randolph Arroo (2016). Polymer-drug nanoconjugate – an innovative nanomedicine: challenges and recent advancements in rational formulation design for effective delivery of poorly soluble drugs. *Pharmaceutical Nanotechnology* 4(1): 38 – 79.
15. **Amos Abioye**; Rachel Armitage; Adeola T. Kola-Mustapha (2016). Thermodynamic changes induced by intermolecular interaction between ibuprofen and chitosan: effect on crystal habit, solubility and in vitro release kinetics of ibuprofen. *Pharmaceutical Research* 33: 337 – 357.
16. Adeola Kola-Mustapha, **Amos Abioye** (2015). Formulation and physical characterization of ibuprofen-DEAE-Dextran nanoconjugates via surfactant solubilization. *West African Journal of Pharmacy* 26(2): 1 – 14.
17. Adeola Kola-Mustapha, **Amos Abioye** (2015). The effect of ibuprofen-DEAE-Dextran nanoconjugates (surfactant solubilization) on the thermal properties and *in vitro* drug release kinetics of ibuprofen. *The Nigerian Journal of Pharmacy* 49(2): 46 – 54.
18. **Amos Abioye**, Sureya Issah, Adeola Kola-Mustapha (2015). *Ex vivo* skin permeation and retention studies on chitosan-ibuprofen-gellan *ternary* nanogel prepared by *in situ* ionic gelation technique – a tool for controlled transdermal delivery of ibuprofen. *International Journal of Pharmaceutics* 490(1-2): 112 – 130.
19. **Amos Abioye**, Adeola Kola-Mustapha (2016). Formulation studies on ibuprofen sodium-cationic dextran conjugate: Effect on tableting and dissolution characteristics of ibuprofen – *Drug Development and Industrial Pharmacy*. 42(1): 39 – 59. DOI 10.3109/03639045.2015.1024684

20. **Amos Abioye**, Adeola Kola-Mustapha (2015). Controlled electrostatic self-assembly of ibuprofen-cationic dextran nanoconjugates prepared by *low energy* green process – a novel delivery tool for poorly soluble drugs – *Pharmaceutical Research* **32(6)**: 2110 - 2131
21. Danil Hammoudi; Adekunle Sanyaolu; Nirav K. Nagarsheth; Jason W. Kimbel; **Amos O. Abioye** (2015). TNF- $\alpha$  inhibitor treatment for Crohn's Disease: comparative review of post therapy malignancy between Infliximab and Adalimumab. *British Journal of Pharmaceutical Research* **5(4)**: 217 – 227
22. **Amos Abioye**, Adeola Kola-Mustapha, George Tangyie Chi, Sunday Iliya (2014). Quantification of *in situ* granulation-induced changes in pre-compression, solubility, dose distribution and intrinsic *in vitro* release characteristics of ibuprofen–cationic dextran conjugate cristanules. *International Journal of Pharmaceutics*, **471 (1–2)**: 453-477
23. **Amos Abioye**, Adeola Kola-Mustapha, Ketan Ruparelia (2014). Impact of in situ granulation and temperature quenching on crystal habit and micromeritic properties of ibuprofen-cationic dextranconjugate cristanules. *International Journal of Pharmaceutics* **462** (2014) 83– 102
24. **Abioye AO**, S.A. Adesida, SB Bamiro, E. Okpako (2011). *In vitro* kinetics of staphylococcal death in the stem bark extracts of *Jatropha curcas* Linn (Euphorbiaceae). *Canadian Journal of Pure and Applied Sciences* **5(2)**: 1465 – 1474
25. Adepoju-Bello A.A, Coker, H.A, **Abioye, A.O**, Ezeagu, I.I, Ayoola, G.A (2011). Solid state interaction of perfloracin with zinc and Aluminium metal ions using Fourier Transform-Infrared spectroscopy. *Nig. Quart. J. Hosp. Med.* **21(3)**: 175-178.
26. Adeleye AI, Ayolabi CI, Ejike LN, **Abioye, A.O**, Omonigbeyin E.A (2009). Antimicrobial and Toxicological Studies of Epa-Ijebu, a 'wonder – cure' concoction used in South West Nigeria. *African Journal of Infectious Diseases.* **3(1)**:  
<http://www.ajol.info/index.php/ajid/issue/view/7309>
27. Adepoju-Bello A.A, Coker, H.A, **Abioye, A.O**, Ayoola, G.A (2009). Interaction between ciprofloxacin and some metal ions. *The J. Pharmaceut. Sci. & Pharm. Prac.* **9 (1)**: 45 – 47
28. Adepoju-Bello A.A, Coker, H.A, Eboka, C.J, **Abioye, A.O**, Ayoola, G.A (2008). The Physicochemical and Antibacterial properties of Ciprofloxacin-Mg<sup>2+</sup> complex. *Nig. Quart. J. Hosp. Med.* **18(3)**: 133-136. <http://www.ajol.info/index.php/nqjhm/issue/view/6355>
29. Adepoju-Bello AA, Coker HAB and **AO Abioye** (2007). Quinolones: A review. *The NigeriaJournal of Pharmacy*, **40**: 58-64.
30. Okwelogu C, Chukwu A, Ifudu, ND, **Abioye AO** (2006). In vitro Release profile of Metronidazole from okra mucilage. *J. Pharm. Sci. Pharm. Pract.* **8(1&2)**: 35-39
31. Solayide A. Adesida, Yekaterina Likhoshvay, William Eisner, Akitoye Olusegun Coker, **Olusegun A. Abioye**, Folasade T. Ogunsola, Barry N. Kreiswirth (2006). Repeats in the 3' region of the proteinA gene is unique in a strain of *Staphylococcus aureus* recovered from wound infections in Lagos, Nigeria. *African Journal of Biotechnology* **5(20)**: 1858-1863

32. Adesida S.A., **Abioye AO**, Bamiro SB, Brai BIC, Smith SI, Amisu KO, Ehichioya DU, Ogunsola FT, Coker AO (2006). Associated Risk factors and Pulsed Gel Electrophoresis of nasal isolates of *Staphylococcus aureus* from Medical Students in a Tertiary Hospital in Lagos, Nigeria. *Brazilian Journal of Infectious Diseases* **11**(1): 63 - 69
33. **Abioye AO**, Coker HAB, Adekoya-Cole T., Giwa SO and Bamiro SB(2005). Randomized Double-Blind Study of the Efficacy, Safety and Tolerability of Tenoxicam versus Diclofenac Sodium in the management of Arthritis and painful musculoskeletal conditions in Adult Nigerian Male and Female Volunteers. *Nig. Quart. J. Hosp. Med.* **15**(4): 186-194
34. **A.O. Abioye**, SB Bamiro, S.A. Adesida , Hunpatin VP and Adeleke T.I. (2004). Preliminary Phytochemical And Antimicrobial Studies Of *Phyllanthus Amarus Linn* (Euphorbiaceae). *Nig. Qt. J. Hosp. Med.* **14**(3): 282-287
35. **A.O. Abioye**, O.M. Odusote, H.A.B. Coker, S.A. Adesida, S.B. Bamiro and L. Aigbomian (2004). Comparative Evaluation of *In-Vitro* Activity of Amoxicillin – Cloxacillin Combination Against Clinical Isolates of *Staphylococcus aureus*. *Nig. Qt. J. Hosp. Med.* **14**(2):199 - 205
36. O.M. Odusote, **A.O. Abioye** and M.O. Rotibi (2002). *Jatropha curcas* Seed Oil Linn (Euphorbiaceae): Contraceptive Activity and an Oral Formulation. *Nig. Qt. J. Hosp. Med.* **12**(1-4): 44-47.
37. **Abioye AO** (2002). Professional Ethics in the Practice of Pharmacy in Nigeria: Yesterday, Today and Tomorrow. Pharmacists in Action a PSN Publication, November, 2002 pp66-74
38. **Abioye AO** (2002). The Antibacterial Resistance: A New Threat. *Nig. J. Pharm.* Jan.- Mar. **33** (1): 6-12
39. Odusote MO, **Abioye AO**, Olagbende-Dada SO, Anyika EN and Adepoju-Bello A (2002). Partnership in Pharmacy Education: University of Lagos First Attempt in Students Industrial Work Experience Scheme. *Nig. J. Pharm.* Jan. – Mar. **33**(1): 42-44
40. M.O. Odusote, **A.O. Abioye**, M.O. Akinleye, M.A. Olagbende-Dada and O.O. Awe (2001). Polyethelene Blend: A novel Vehicle for Coloured Cosmetics. *J. Pharmaceut. Sci. Pharm. Pract.* **7**(12):100-105
41. **Abioye AO**, Odusote MO, Ifudu ND and Silva BO (2001). In vitro Release Kinetics of Salicylic Acid from *Cissus populnea* Gel. *J. Pharm. Sci. Pharm. Pract.* **7**(12): 113-118
42. Odusote MO, Ifudu ND, Oladimeji OO, **Abioye AO** and Odusote OO (2001). Oral Hygiene Formulations: *Distemonanthus benthamianus* Family Casealpinaeae. *J. Pharm. Sci. & Pharm. Pract.* **7**(1): 33-38
43. Odusote MO, Igwilo CI and **Abioye AO** (2000). Characterization of some Nigerian gums towards utilization as pharmaceutical excipients. *Nig. Qt. J. Hosp. Med.* **10**(3): 185 - 191
44. **Abioye AO**, Odusote MO and Ifudu ND(2000). Evaluation of *Cissus populnea* Gum As a Potential Emulsifying Agent. *J. Pharm. Sci. & Pharm. Prac.* **6**(2): 49-53.

45. **Abioye AO**, Odusote MO and Igwilo CI (2000). Studies on the potential use of a Polysaccharide gum derived from *Cissus populnea* Guill & Perr (Ampelidaceae) as a Suspending Agent. J. Pharm. Sci. & Pharm. Prac. **6**(2): 33-37.
46. **Abioye AO**, Odusote MO, Ifudu ND and Silva BO (2000). A Physicochemical Basis for the Stability Effect of *Cissus populnea* Gum in Oil - in - Water Extemporaneous Emulsions. J. Pharm. Sci. & Pharm. Prac. **6**(1): 17-22.
47. **Abioye AO**, Odusote MO, Ifudu ND and Silva BO (2000). Studies on the Surface Activity of a polysaccharide gum derived from *Cissus populnea* Guill & Perr (Ampelidaceae) : A potential Pharmaceutical Excipient. J. Pharm. Sci. & Pharm. Prac. **6**(1): 5-9.
48. Odusote, M.O and **Abioye, A.O.** (2000). Studies on Locally Sourced Gelatin as an Ointment Base. Pharmacy Practice and Continuing Education **3** (2): 10 - 18.
49. Odusote M.O. **Abioye A.O.** Coker H.A.B. (1999). The Latex of *Jatropha curcas* Linn (Euphorbiaceae): A prospective Haemostatic Agent. Nigerian Quarterly Journal Hospital Medicine **9**(2): 158-166.
50. Odusote M.O., **Abioye A.O.** Coker H.A.B., Muoneke B.C. (1996)., Potent Bacteriostatic Activity of the Latex of *Jatropha curcas* Linn (Euphorbiaceae): A basis for its wound healing effects. Nigerian Quarterly Journal Hospital Medicine **6** (4): 327-333

### **III. Proceedings of Conferences and Symposia (Poster / Oral Presentation)**

51. Maitham Naqvi, Dillan Pattni, Aderonke Ayinke Adepoju-Bello, and **Amos Abioye**, 2021. Non-intuitive Behaviour of Polymer-Ciprofloxacin Nanoconjugate Suspensions: A Tool for Flexible Oral Drug Delivery. AAPS Conference, PharmSci 360, PA Convention Centre, Philadelphia, Pensivania, US, October 17 – 20, 2021.
52. Pathum Wijesekara, Geoff Smith, Paul Matejtschuk, and **Amos Abioye**, 2021. Application of Through-Vial Impedance Spectroscopy (TVIS) to Investigate the Primary-Drying Endpoint during the Freeze-Drying of IgG Solutions. AAPS Conference, PharmSci 360, PA Convention Centre, Philadelphia, Pensivania, US, October 17 – 20, 2021.
53. Dudzinska, P., Adepoju-Bello, A.A., Sanyaolu, A., Abioye, A.O., Coker, H.B. (2019). Rational formulation of ciprofloxacin-chitosan nanoplexes for enhanced in vitro drug release and extended synergistic antimicrobial potency. AAPS Conference, PharmSci 360, Henry B. Gonzalez Convention Centre, San Antonio, Texas, US, November 3 – 6, 2019.
54. Abioye, A.O., Kola-Mustapha, A.T. (2017). Eco-friendly counter-ion conjugation: a novel formulation strategy for extended release of poorly soluble drugs in polymeric nanocarriers. AAPS Conference, San Diego Convention Centre, US, November 13 – 17, 2017.
55. Abioye, A.O., (2017). Amplified counter-ion conjugation: a novel eco-friendly strategy for extended release of poorly soluble drugs from polymeric nanocarriers. EPSRC International Networking Workshop on July 13 2017 at the University College London (UCL).

56. Kola-Mustapha, A.T., Abioye, A.O. (2016). Combined polymer-drug self-assembly and in situ hydrotropic complexation: a novel synergistic strategy for the delivery of ibuprofen EUFEPS Conference, Turkey November, 2016.
57. Kola-Mustapha, A.T., Abioye, A.O. (2016). Aqueous polyelectrolyte nanomatrix films: a novel 'green' self-assembly strategy for the delivery of poorly soluble drugs. AAPS Conference, Colorado Convention Centre, Denver, US, November 13 – 17, 2016.
58. Abioye, A.O. Personalization of Medicines. 44<sup>th</sup> Interpharm Conference, Macdonald Craxton Wood Hotel, Parkgate Road, Ledsham, Chester, CH66 9PB, UK, May 11 – 13, 2016.
59. Abioye, A.O., Kola-Mustapha, A.T. (2015). Thermodynamic changes induced by ibuprofen-chitosan nanoparticle complex: effect on crystal habit, solubility and in vitro release kinetics of ibuprofen. AAPS Conference, Orlando Florida, US, October 25 – 29, 2015
60. Dhariwal, S.; Issah, S.; Kola-Mustapha, A.T.; Abioye, A.O. (2015). Amplified intermolecular attraction between ibuprofen and chitosan: effect on crystal behaviour and in vitro release kinetics of ibuprofen. 6<sup>TH</sup> APS International PharmSci Conference, Nottingham, UK, 7 – 9 September, 2015.
61. Kola-Mustapha A.T. and Abioye A. O. (2014), In vitro release mechanisms of Ibuprofen from cationic dextran-gellan nanoconjugates, poster presented at the Association of Pharmaceutical Scientists UK-Pharmsci Conference, University of Hertfordshire, United Kingdom. September 2014.
62. Kola-Mustapha A.T. and Abioye A. O. (2013), Release kinetics of ibuprofen from Gellan-cationic Dextran conjugate hydrogels, poster presented at the American Association of Pharmaceutical Scientists Meeting and Exposition San Antonio, USA, November 2013.
63. Kola-Mustapha A.T., Abioye A. O. and Schindwein, W. (2012). Drug Release Kinetics of Ibuprofen Microparticles in Carbopol Gel Formulations, poster presented at the Association of Pharmaceutical Scientists UK-PharmSci Conference, University of Nottingham, United Kingdom, September 2012.
64. Dan Fei, **Amos Abioye**, Benjamin Dalbi (2009). Preliminary evaluation of the binding capacity of pullulan in ibuprofen granules. Association of Pharmaceutical Scientists UK-PharmSci Conference, University of Manchester, UK.
65. Odusote, M.O., **Abioye, A.O.**, Silva, B.O. (1999). Studies on the surface activity of a polysaccharide gum derived from *Cissus populnea* Guill & Perr (Ampelidaceae): a potential pharmaceutical excipient. Book of Abstracts #755: Society for Medicinal Plants and Natural Products Research Conference, Leiden University, Amsterdam, The Netherlands, July, 1999.
66. Odusote, M.O., **Abioye, A.O.** (1999). Studies on the potential use of a polysaccharide gum derived from *Cissus populnea* Guill & Perr (Ampelidaceae) as a suspending agent. Book of Abstracts #756: Society for Medicinal Plants and Natural Products Research Conference, Leiden University, Amsterdam, The Netherlands, July, 1999.

## **G. Other Professional Activities at Palm Beach Atlantic University**

Member of Standing Committees at the School and University levels

1. Member, Curriculum and Academic Policies Committee (2018 – 2020)
2. Chair, Curriculum and Academic Policies Committee (2019 – 2020)
3. Member, Faculty Recruitment Committee (2019 – 2020)
4. Member, Inter-professional Education Committee (2018 – present)
5. Member, Students' Advocacy Committee (2020 – present)
6. Secretary, Undergraduate Programs Committee (2019 – 2020)

## **H. Membership of Professional / Scientific Organizations**

1. Fellow Royal Society of Chemistry, UK
2. Fellow, Higher Education Academy, UK
3. Registered Pharmacist with General Pharmaceutical Council (GPhC) UK
4. Registered Pharmacist with Pharmacists Council of Nigeria (PCN)
5. Member, Royal Pharmaceutical Society, UK
6. Member, American Association of Colleges of Pharmacy, USA
7. Member, American Association of Pharmaceutical Scientists, USA
8. Member, American Society for Microbiology, USA.
9. Member, Institute of Public Analyst, Nigeria
- 10 Member, Academy of Pharmaceutical Scientists, UK
- 11 Member, Institute of Clinical Research, UK

## **I. Honors and Awards**

AAPS PharmSci360 Best Abstract Award	2021
GSOP Dean's Award for Faculty Innovation, PBA (Integra Connect)	2021
AAPS President's Letter of Commendation	2020
Vice Chancellor's Distinguished Teaching Award, DMU	2015
Outstanding Contribution to Reviewing, ELSEVIER	2015
Vice Chancellor's Commendation, University of Malawi	2009
Fellow of the Royal Society of Chemistry, UK	2009 – Present
Fellow of the Higher Education Academy, UK	2009 – Present
Vice Chancellor Commendation, University of Ibadan	2004 – 2006

## **J. Volunteering Services**

### ***AAPS Poster Abstract Reviewer/Screeener***

- *2017 AAPS Annual Meeting and Exposition*
- *2019 AAPS Annual Meeting and Exposition*
- *2020 AAPS Annual Meeting and Exposition*
- *2021 AAPS Annual Meeting and Exposition*

### **AAPS Poster Forum Host**

- 2017 AAPS Annual Meeting and Exposition

### **Visiting Professor to the New Department of Pharmacy University of Malawi, Africa 2008 - 2010**

- Pharmacy Curriculum Review
- Teaching Pharmaceutics and Pharmaceutical Sciences
- Sharing Best Teaching Practice

### **Visiting Professor to Wuhan University of Technology, China 2014**

- Teaching Pharmaceutics and Pharmaceutical Sciences

### **External Examiner for B.Pharm Degree**

Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, University of Ibadan – B.Pharm. Degree Examination **2003/2004; 2004/ 2005, 2005/06**

### **Internal Examiner for Postgraduate Degree**

- Department of Medical Microbiology and Parasitology, College of Medicine, University of Lagos – Ph.D. Degree Examination **2002 – 2007**
- Leicester School of Pharmacy, De Montfort University – Internal Assessor for Ph.D. students' annual review and MPhil / Ph.D. transfer reports **2007 – 2018**

### **Journal Reviewer for International Journals**

- International Journal of Pharmaceutics, UK (Outstanding Reviewer of year 2015 Award)
- AAPS Pharmaceutical Research, USA
- AAPS Journal, USA
- AAPS PharmSciTech, USA
- Molecular Pharmaceutics
- Drug Delivery Letters
- Current Analytical Chemistry (Bentham Science Publishers)
- International Journal of Nanomedicine (Dove Medical Press, NZ)
- Drug Design, Development and Therapy (Dove Medical Press, NZ)
- Int. J. Environmental Research and Public Health
- African J. Biotechnology etc.

**K. RESEARCH SUPERVISION – NUMEROUS BPharm., BSc., MPharm., MSc. and Ph.D.  
Research Students (1997 – 2018)**

**L. HOBBIES:** Singing (Music), Soccer

**M. REFEREES:** Available on request.